SMMT
Income statement / Annual
Last year (2024), Summit Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Summit Therapeutics Inc.'s net income was -$221.32 M.
See Summit Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
01/31/2019 |
01/31/2018 |
01/31/2017 |
01/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$704,295.00 |
$1.81 M |
$860,000.00 |
$632,017.82 |
$56.41 M |
$35.98 M |
$2.88 M |
$0.00 |
| Cost of Revenue |
$15.01 M
|
$2.05 M
|
$2.51 M
|
$0.00
|
$0.00
|
$155,399.25
|
$24,919.00
|
$97,667.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$15.01 M
|
-$2.05 M
|
-$1.81 M
|
$1.81 M
|
$860,000.00
|
$476,618.57
|
$56.39 M
|
$35.88 M
|
$2.88 M
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
-2.57
|
1
|
1
|
0.75
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$150.78 M
|
$59.47 M
|
$52.00 M
|
$85.35 M
|
$53.27 M
|
$32.71 M
|
$51.38 M
|
$41.01 M
|
$23.69 M
|
$23.94 M
|
| General & Administrative Expenses |
$60.53 M
|
$30.27 M
|
$26.70 M
|
$23.61 M
|
$19.23 M
|
$7.24 M
|
$16.19 M
|
$16.98 M
|
$10.35 M
|
$7.45 M
|
| Selling & Marketing Expenses |
$0.00
|
-$2.05 M
|
$0.00
|
$0.00
|
$0.00
|
$2.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$60.53 M
|
$28.22 M
|
$26.70 M
|
$23.61 M
|
$19.23 M
|
$9.30 M
|
$16.19 M
|
$16.98 M
|
$10.35 M
|
$7.45 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$14.42 M
|
-$20.97 M
|
-$19.31 M
|
$0.00
|
-$19.88 M
|
-$3.86 M
|
-$1.95 M
|
-$3.14 M
|
| Operating Expenses |
$211.30 M
|
$87.69 M
|
$64.28 M
|
$88.00 M
|
$53.19 M
|
$42.00 M
|
$47.69 M
|
$54.13 M
|
$33.94 M
|
$29.45 M
|
| Cost And Expenses |
$226.31 M
|
$89.74 M
|
$64.28 M
|
$88.00 M
|
$53.19 M
|
$43.40 M
|
$47.69 M
|
$54.13 M
|
$33.94 M
|
$29.45 M
|
| Interest Income |
$0.00
|
$10.40 M
|
$1.51 M
|
$178,951.00
|
$4,000.00
|
$4,336.32
|
$3.66 M
|
$4.38 M
|
$9,999.63
|
$30,000.00
|
| Interest Expense |
-$8.69 M
|
$16.46 M
|
$4.40 M
|
$281,000.00
|
$255,000.00
|
$32,522.00
|
$556,102.00
|
$1.65 M
|
$1.08 M
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$90.74 M
|
$2.51 M
|
$2.46 M
|
$2.00 M
|
$1.39 M
|
$1.49 M
|
$348,205.00
|
$72,497.00
|
$68,361.00
|
| EBITDA |
$313,000.00 |
$1.00 M |
-$52.63 M |
-$62.74 M |
-$37.13 M |
-$16.80 M |
$11.66 M |
-$32.19 M |
-$30.98 M |
-$20.30 M |
| EBITDA Ratio |
0
|
0
|
-86.33
|
-47.64
|
-59.85
|
-65.46
|
0.25
|
-0.37
|
-10.76
|
0
|
| Operating Income Ratio |
0
|
0
|
-102.36
|
-47.64
|
-61.85
|
-67.66
|
0.22
|
-0.51
|
-10.79
|
0
|
| Total Other Income/Expenses Net |
-$221.63 M
|
-$526.14 M
|
-$19.15 M
|
-$24.87 M
|
-$14.01 M
|
-$1.04 M
|
-$3.30 M
|
$1.91 M
|
-$854,000.00
|
$5.54 M
|
| Income Before Tax |
-$221.32 M
|
-$615.87 M
|
-$78.78 M
|
-$88.60 M
|
-$52.91 M
|
-$28.41 M
|
$6.60 M
|
-$15.42 M
|
-$32.13 M
|
-$28.69 M
|
| Income Before Tax Ratio |
0
|
0
|
-111.86
|
-48.98
|
-61.52
|
-44.95
|
0.12
|
-0.43
|
-11.16
|
0
|
| Income Tax Expense |
$0.00
|
-$946,000.00
|
-$4.40 M
|
-$2.46 M
|
-$213,000.00
|
-$4.52 M
|
-$3.27 M
|
-$5.32 M
|
-$5.42 M
|
-$4.36 M
|
| Net Income |
-$221.32 M
|
-$614.93 M
|
-$74.38 M
|
-$86.15 M
|
-$52.70 M
|
-$23.88 M
|
$9.87 M
|
-$10.09 M
|
-$26.71 M
|
-$24.34 M
|
| Net Income Ratio |
0
|
0
|
-105.61
|
-47.62
|
-61.28
|
-37.79
|
0.17
|
-0.28
|
-9.28
|
0
|
| EPS |
-0.31 |
-0.99 |
-0.38 |
-0.93 |
-0.76 |
-0.148 |
0.11 |
-0.16 |
-0.43 |
-0.41 |
| EPS Diluted |
-0.31 |
-0.99 |
-0.38 |
-0.93 |
-0.76 |
-0.148 |
0.11 |
-0.15 |
-0.43 |
-0.41 |
| Weighted Average Shares Out |
$718.54 M
|
$619.65 M
|
$193.34 M
|
$92.24 M
|
$69.52 M
|
$164.15 M
|
$86.14 M
|
$65.03 M
|
$61.55 M
|
$59.10 M
|
| Weighted Average Shares Out Diluted |
$718.54 M
|
$619.65 M
|
$193.34 M
|
$92.24 M
|
$69.52 M
|
$164.15 M
|
$86.14 M
|
$65.43 M
|
$61.55 M
|
$59.10 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
